To authorize the Secretary of Defense to carry out a program to support the defense biotechnology supply chain, and for other purposes.

1) What happened: On September 8, 2025, Rep. Khanna (D-CA-17) introduced HR5186, a bill authorizing the Secretary of Defense to establish a Biotechnology Supply Chain Resiliency Program. The bill was referred to the House Committee on Armed Services and has not advanced beyond that stage. As of April 29, 2026, the bill is in early legislative stages with only 2 cosponsors. The bill's sponsor is a junior member, indicating lower near-term passage probability without a broader bipartisan coalition. 2) The money trail: This bill authorizes the DoD to establish a program and enter into contracts, grants, cooperative agreements, and OTAs — it does NOT appropriate any specific dollar amount. The bill language is permissive ('may establish') not mandatory ('shall establish'). Actual funding would require a subsequent appropriation through the NDAA or a standalone appropriations bill. The related bill S1071 (NDAA for FY2026) became law as PL 119-60 — this HR5186's provisions could be incorporated into a future NDAA as a policy rider, which is the most likely path to actual funding. 3) Structural winners and losers: The primary beneficiaries are companies with existing DoD or federal biomanufacturing relationships. Ginkgo Bioworks ($DNA), currently trading at $7.85 near its 52-week low of $5.37, has the most direct exposure as a pure-play synthetic biology platform with existing government contracts. ADM ($72.80) benefits as a large-scale agricultural processor that can pivot existing infrastructure to defense-grade chemical and fuel production. DuPont ($45.33) benefits as a specialty materials supplier but the impact is diluted by its diversified business. Companies without existing biomanufacturing or DoD contracting capability are unlikely to benefit in the near term. 4) Real market data analysis: As of April 28, 2026, $DNA trades at $7.85 with a 30-day gain of +32.38% despite a 7-day decline of -6.99% — this suggests significant near-term volatility and potential speculative interest in biodefense plays. $ADM shows a 7-day gain of +4.85% and is trading near its 52-week high of $74.19, reflecting broader strength in agricultural commodities rather than specific legislative catalysts. $DD is down -1.41% over 7 days, showing no immediate market reaction to this early-stage bill. The Presidential Memorandum on DPA Section 303 for domestic petroleum does not directly compete — it reinforces a parallel domestic production strategy but does not contractually redirect funds away from bio-based alternatives. 5) Timeline: The bill requires House Armed Services Committee markup, floor passage, Senate companion and passage, and conference committee reconciliation before reaching the President. Given early-stage status (referred to committee 7+ months ago with no further action) and only 2 cosponsors, expect this to move — if at all — as a provision in a future NDAA (FY2027 or later). The legislative pace is slow; no near-term catalyst is present.